Known risk factors include among others success in preclinical and clinical trials especially if based on a small patient sample does not ensure that later clinical trials will be successful the data presented in this release may not be consistent with the final data set and analysis or result in an assessment that SRP9001 provides a safe or effective treatment benefit different methodologies or assumptions than we utilize to assess particular safety or efficacy parameters may yield different statistical results and even if we believe the data collected from clinical trials are positive the data may not be sufficient to support approval by the FDA or foreign regulatory authorities we may not be able to execute on our business plans and goals including meeting our expected or planned regulatory milestones and timelines clinical development plans and bringing our product candidates to market due to a variety of reasons many of which are outside of our control including possible limitations on company financial and other resources manufacturing limitations that may not be anticipated or resolved for in a timely manner regulatory court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates the impact of the COVID19 pandemic and those risks identified under the heading Risk Factors in our most recent Annual Report on Form 10K for the year ended December 31 2019 and most recent Quarterly Report on Form 10Q filed with the Securities and Exchange Commission SEC as well as other SEC filings we make which you are encouraged to review